Over 1,000 Chemotherapy Protocols And Counting

International, multicenter, randomized, open-label, phase 3 trial Age ≥60 years, IDH2 gene mutated, de novo or secondary AML Previously 2 or 3 prior AML- directed therapies Enasi

20 May

Biliary Tract Cancer

New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer

Phase III, double-blind, randomized, controlled, multicenter, open-label trial (KEYNOTE-966) Previously untreated, unresectable, locally advanced or metastatic biliary tract cancer

24 Jun

Ovarian Cancer

New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer

A Phase III, Randomized, Open-label trial (MIRASOL) Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate recep

20 Nov

GastroEsophageal Cancer

New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer

Randomized, open-label, phase 3 trial Potentially resectable, locally advanced cT3-4 gastric adenocarcinoma in patients younger than 60 years Neoadjuvant Docetaxel, Oxaliplatin, Ca

20 Nov

Prostate Cancer

New Reference: Enzalutamide in Recurrent Prostate Cancer

Phase 3, randomized, international trial (EMBARK)) Adult patients with prostate cancer who had biochemical recurrence after local therapy and meet the following criteria at screeni

20 Nov

Chronic Lymphocytic Leukemia

New Indication: Pirtobrutinib in CLL

Open-label, multi-center Phase 1/2 study (BRUIN) Relapse/Refractory CLL/SLL who had previously received a BTK inhibitor Pirtobrutinib (n=317)

20 Nov

Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

Investigator-initiated, open-label, single-arm, multi-institutional, phase II trial (TAB) Adult patients with HER2-positive, treatment-naïve BTCs Trastuzumab + Gemcitabine + Cispl

20 Nov

Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Multi-center, phase 2 nonrandomized clinical trial (UNICORN) Previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion muta

20 Nov

Thyroid Cancer

New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer

Phase 3, randomized trial (LIBRETTO-531) RET mutant, unresectable, locally advanced or metastatic medullary thyroid cancer and no history of treatment with kinase inhibitors Selpe

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries